Based on the provided sources, it is not possible to determine if there have been any new patents filed for olaparib in the United States. The sources provided do not specifically mention any recent patent filings for olaparib in the US.

The first source, DrugPatentWatch, provides information about the drug olaparib, including its trade name and patent status. However, it does not provide specific details about recent patent filings for olaparib in the US.

The second source, a PDF document from AstraZeneca, contains information about the company's full-year and Q4 2022 results. While it may provide information about the drug olaparib and its sales performance, it does not mention any new patents filed for the drug.

The third source is a decision from the European Patent Office (EPO) regarding olaparib. While this source may provide insights into the patent status of olaparib in Europe, it does not provide information about new patent filings in the US.

To obtain accurate and up-to-date information about new patent filings for olaparib in the US, it would be advisable to consult official patent databases such as the United States Patent and Trademark Office (USPTO) database. These databases would provide the most reliable and comprehensive information on patent filings for olaparib in the US.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/OLAPARIB
[2] AstraZeneca: Full-year and Q4 2022 results announcement PDF
[3] European Patent Office (EPO): Decision T 1908/14